North America Human Insulin Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

North America Human Insulin Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Country Analysis

North America Human Insulin Market Analysis 2026

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
North America Human Insulin Totalxxxxxxxxxxxxxxxx
United Statesxxxxxxxxxxxxxxxx
Canadaxxxxxxxxxxxxxxxx
Mexicoxxxxxxxxxxxxxxxx

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis

Analog insulin is expected to lead the worldwide human insulin market and is expected to grow at a quicker rate in the upcoming years. Given the benefits that analog insulin still has over human insulin, this market development is expected. As a result, within the last five years, there has been an increased requirement for analog insulin. Moreover, the recent introduction of generic insulin is expected to stimulate the expansion of the human insulin market. In 2021, Insulin Lispro—a generic version of the fast-acting analog insulin Humalog—was introduced by Eli Lilly and Company. Due to its half the price of Humalog, patients with diabetes will be able to get it for less money in the US. Because the pharmaceutical class is expected to be less widely adopted, conventional human insulin is expected to develop at a slower compound annual growth rate (CAGR) than analog insulin. The improved efficacy and response rate of analog insulin is the cause of this particular market trend, even though classic human insulin is currently offered in several variations.

Analogue insulin North America Human Insulin Market Analysis
XX
Analogue insulin Market Size 2025
XX %
CAGR
Locked · Full data in paid report
Traditional human insulin North America Human Insulin Market Analysis
XX
Traditional human insulin Market Size 2025
XX %
CAGR
Locked · Full data in paid report

Market size by (Illustrative, 2025)
Share distribution (2025)

Disclaimer: The charts and graphs are for illustrative purposes only and do not represent actual market values. To access accurate quantitative data, please request a paid report or request free sample.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the  Human Insulin Market

The major players in the market are adopting various strategies to lead the market. They are using different strategies like comparing the revenue, expenses, resources, product portfolio, region coverage, market share, and key initiatives. The key market players are also constantly focusing on R&D so that they can provide the most effective and cost-effective solution. They are also strengthening the market through innovation, brand reputation, and leadership. The companies are using various strategies to lead the market. This was about the various strategies that are used by the key market players to lead the market.

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Novo Nordisk A/S••• ••• ••• •••
Eli Lilly and Company••• ••• ••• •••
Sanofi••• ••• ••• •••
Biocon••• ••• ••• •••
Tonghua Dong Bao Pharmaceutical Co. Inc.••• ••• ••• •••
Pfizer Inc.••• ••• ••• •••
Wockhardt••• ••• ••• •••
Julphar••• ••• ••• •••
Bristol-Myers Squibb Company••• ••• ••• •••
GlaxoSmithKline Plc••• ••• ••• •••
Oramed pharmaceutical••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the North America Human Insulin market size was valued at USD xx billion in 2024 and is expected to reach USD xx billion at a CAGR of xx% during the forecast period.

Due to a sedentary lifestyle and high diabetes prevalence, North America particularly the United States dominates the global market for human insulin. The primary issue in the United States, where insulin makers receive about half of their revenue from domestic sales, is cost. Global sales of Lantus, a long-acting insulin, are highest in the United States. The majority of manufacturers of diabetes medications view the nation as a crucial market for increasing overall worldwide sales. With a commanding market share in the US, Lantus is the basal insulin that is most frequently used worldwide. The market for conventional human insulin drugs in North America is anticipated to expand. 
The largest market share is Humulin, followed by Novolin. In the United States, there are no generic competitors for the conventional North American human insulin medication market. With more than 56% of the global market, the United States is the country with the most Humalog sales. Most manufacturers of diabetes medications view the nation as a crucial market for increasing overall worldwide sales.
•    For instance, according to the report by IDF Diabetes Atlas, there are around 1 in 7, and 51 million people are suffering from diabetes in the North American region, and USD 415 billion was spent in 2021.

(Source:https://diabetesatlas.org/).

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The North America Human Insulin Market Analysis is witnessing significant growth in the near future.

In 2023, the Analogue insulin segment accounted for a notable share of the North America Human Insulin Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

North America Human Insulin Market Analysis market size and growth rate is provided in the report covering 2021-2025 historical and 2025-2033 forecast data.
Major factors including drivers, restraints, opportunities and challenges are analyzed with detailed insights.
Top manufacturers Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Biocon, Tonghua Dong Bao Pharmaceutical Co. Inc., Pfizer Inc., Wockhardt, Julphar, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Oramed pharmaceutical and others are profiled in the report.
Segments include Product Type, Diabetes and additional sub-segments.
Regional analysis covers all major markets. The report identifies the dominant region and provides country-level data.
Sample pages can be obtained on demand from the website. 24/7 chat support and direct call services are available.

★ Reviews

Rate this report

North America Human Insulin Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).
Report Scope
TypeRegular Human Insulin, Isophane Insulin (NPH), Premixed Insulin
ApplicationType 1 Diabetes, Type 2 Diabetes
Distribution ChannelHospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others
End-UserHospitals, Clinics, Home Care Settings
Dosage FormInjectable Insulin, Insulin Pumps
Conclusion
List of CompetitorsEli Lilly and Company, Novo Nordisk AS, Sanofi SA, Biocon Ltd, Wockhardt Ltd, Dr. Reddys Laboratories Ltd, Viatris, Abbott Laboratories, Zhejiang Hisun Pharmaceutical Co Ltd, Lupin Limited, Others

  • Chapter 1. Competitor Analysis (Subject to Data Availability (Private Players))

    • 1.1 Top Competitors Analysis
      • 1.1.1 Top Players Ranking 2024
      • 1.1.2 New Product Launch Analysis
    • 1.2 Company Profile (Data Subject to Availability) Sample Format
      • 1.2.1 Eli Lilly and Company
        • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.1.2 Business Overview
        • 1.2.1.3 R&D Investment (Subject to data availability)
        • 1.2.1.4 Financials (Subject to data availability)
        • 1.2.1.5 Product Types Specification
        • 1.2.1.6 Business Strategy
        • 1.2.1.7 Recent Developments
        • 1.2.1.8 Management Change
        • 1.2.1.9 S.W.O.T Analysis
      • 1.2.2 Novo Nordisk AS
        • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.2.2 Business Overview
        • 1.2.2.3 R&D Investment (Subject to data availability)
        • 1.2.2.4 Financials (Subject to data availability)
        • 1.2.2.5 Product Types Specification
        • 1.2.2.6 Business Strategy
        • 1.2.2.7 Recent Developments
        • 1.2.2.8 Management Change
        • 1.2.2.9 S.W.O.T Analysis
      • 1.2.3 Sanofi SA
        • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.3.2 Business Overview
        • 1.2.3.3 R&D Investment (Subject to data availability)
        • 1.2.3.4 Financials (Subject to data availability)
        • 1.2.3.5 Product Types Specification
        • 1.2.3.6 Business Strategy
        • 1.2.3.7 Recent Developments
        • 1.2.3.8 Management Change
        • 1.2.3.9 S.W.O.T Analysis
      • 1.2.4 Biocon Ltd
        • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.4.2 Business Overview
        • 1.2.4.3 R&D Investment (Subject to data availability)
        • 1.2.4.4 Financials (Subject to data availability)
        • 1.2.4.5 Product Types Specification
        • 1.2.4.6 Business Strategy
        • 1.2.4.7 Recent Developments
        • 1.2.4.8 Management Change
        • 1.2.4.9 S.W.O.T Analysis
      • 1.2.5 Wockhardt Ltd
        • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.5.2 Business Overview
        • 1.2.5.3 R&D Investment (Subject to data availability)
        • 1.2.5.4 Financials (Subject to data availability)
        • 1.2.5.5 Product Types Specification
        • 1.2.5.6 Business Strategy
        • 1.2.5.7 Recent Developments
        • 1.2.5.8 Management Change
        • 1.2.5.9 S.W.O.T Analysis
      • 1.2.6 Dr. Reddys Laboratories Ltd
        • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.6.2 Business Overview
        • 1.2.6.3 R&D Investment (Subject to data availability)
        • 1.2.6.4 Financials (Subject to data availability)
        • 1.2.6.5 Product Types Specification
        • 1.2.6.6 Business Strategy
        • 1.2.6.7 Recent Developments
        • 1.2.6.8 Management Change
        • 1.2.6.9 S.W.O.T Analysis
      • 1.2.7 Viatris
        • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.7.2 Business Overview
        • 1.2.7.3 R&D Investment (Subject to data availability)
        • 1.2.7.4 Financials (Subject to data availability)
        • 1.2.7.5 Product Types Specification
        • 1.2.7.6 Business Strategy
        • 1.2.7.7 Recent Developments
        • 1.2.7.8 Management Change
        • 1.2.7.9 S.W.O.T Analysis
      • 1.2.8 Abbott Laboratories
        • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.8.2 Business Overview
        • 1.2.8.3 R&D Investment (Subject to data availability)
        • 1.2.8.4 Financials (Subject to data availability)
        • 1.2.8.5 Product Types Specification
        • 1.2.8.6 Business Strategy
        • 1.2.8.7 Recent Developments
        • 1.2.8.8 Management Change
        • 1.2.8.9 S.W.O.T Analysis
      • 1.2.9 Zhejiang Hisun Pharmaceutical Co Ltd
        • 1.2.9.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.9.2 Business Overview
        • 1.2.9.3 R&D Investment (Subject to data availability)
        • 1.2.9.4 Financials (Subject to data availability)
        • 1.2.9.5 Product Types Specification
        • 1.2.9.6 Business Strategy
        • 1.2.9.7 Recent Developments
        • 1.2.9.8 Management Change
        • 1.2.9.9 S.W.O.T Analysis
      • 1.2.10 Lupin Limited
        • 1.2.10.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.10.2 Business Overview
        • 1.2.10.3 R&D Investment (Subject to data availability)
        • 1.2.10.4 Financials (Subject to data availability)
        • 1.2.10.5 Product Types Specification
        • 1.2.10.6 Business Strategy
        • 1.2.10.7 Recent Developments
        • 1.2.10.8 Management Change
        • 1.2.10.9 S.W.O.T Analysis
      • 1.2.11 Others
        • 1.2.11.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
        • 1.2.11.2 Business Overview
        • 1.2.11.3 R&D Investment (Subject to data availability)
        • 1.2.11.4 Financials (Subject to data availability)
        • 1.2.11.5 Product Types Specification
        • 1.2.11.6 Business Strategy
        • 1.2.11.7 Recent Developments
        • 1.2.11.8 Management Change
        • 1.2.11.9 S.W.O.T Analysis

  • Chapter 2. Global Human Insulin Market Analysis

    • 2.1 Global Human Insulin Market Analysis
    • 2.2 Global Human Insulin Market Analysis by Type
    • 2.3 Global Human Insulin Market Analysis by Application
    • 2.4 Global Human Insulin Market Analysis by Distribution Channel
    • 2.5 Global Human Insulin Market Analysis by End-User
    • 2.6 Global Human Insulin Market Analysis by Dosage Form
    • 2.7 Global Human Insulin Market Analysis by Conclusion

  • Chapter 3. North America Human Insulin Market Analysis

    • 3.1 North America Human Insulin Market Analysis
    • 3.2 North America Human Insulin Market Analysis by Country
    • 3.3 North America Human Insulin Market Analysis by Type
    • 3.4 North America Human Insulin Market Analysis by Application
    • 3.5 North America Human Insulin Market Analysis by Distribution Channel
    • 3.6 North America Human Insulin Market Analysis by End-User
    • 3.7 North America Human Insulin Market Analysis by Dosage Form
    • 3.8 North America Human Insulin Market Analysis by Conclusion
    • 3.9 North America Human Insulin Market Analysis by Key Players

  • Chapter 4. United States Human Insulin Market Analysis

    • 4.1 United States Human Insulin Market Analysis
    • 4.2 United States Human Insulin Market Analysis by Type
    • 4.3 United States Human Insulin Market Analysis by Application
    • 4.4 United States Human Insulin Market Analysis by Distribution Channel
    • 4.5 United States Human Insulin Market Analysis by End-User
    • 4.6 United States Human Insulin Market Analysis by Dosage Form
    • 4.7 United States Human Insulin Market Analysis by Conclusion
    • 4.8 United States Human Insulin Market Analysis by Key Players

  • Chapter 5. Canada Human Insulin Market Analysis

    • 5.1 Canada Human Insulin Market Analysis
    • 5.2 Canada Human Insulin Market Analysis by Type
    • 5.3 Canada Human Insulin Market Analysis by Application
    • 5.4 Canada Human Insulin Market Analysis by Distribution Channel
    • 5.5 Canada Human Insulin Market Analysis by End-User
    • 5.6 Canada Human Insulin Market Analysis by Dosage Form
    • 5.7 Canada Human Insulin Market Analysis by Conclusion
    • 5.8 Canada Human Insulin Market Analysis by Key Players

  • Chapter 6. Mexico Human Insulin Market Analysis

    • 6.1 Mexico Human Insulin Market Analysis
    • 6.2 Mexico Human Insulin Market Analysis by Type
    • 6.3 Mexico Human Insulin Market Analysis by Application
    • 6.4 Mexico Human Insulin Market Analysis by Distribution Channel
    • 6.5 Mexico Human Insulin Market Analysis by End-User
    • 6.6 Mexico Human Insulin Market Analysis by Dosage Form
    • 6.7 Mexico Human Insulin Market Analysis by Conclusion
    • 6.8 Mexico Human Insulin Market Analysis by Key Players

  • Chapter 7. Type Analysis

    • 7.1 Regular Human Insulin
    • 7.2 Isophane Insulin (NPH)
    • 7.3 Premixed Insulin

  • Chapter 8. Application Analysis

    • 8.1 Type 1 Diabetes
    • 8.2 Type 2 Diabetes

  • Chapter 9. Distribution Channel Analysis

    • 9.1 Hospital Pharmacies
    • 9.2 Retail Pharmacies
    • 9.3 Online Pharmacies
    • 9.4 Others

  • Chapter 10. End-User Analysis

    • 10.1 Hospitals
    • 10.2 Clinics
    • 10.3 Home Care Settings

  • Chapter 11. Dosage Form Analysis

    • 11.1 Injectable Insulin
    • 11.2 Insulin Pumps

  • Chapter 12. Conclusion Analysis

  • Chapter 13. Qualitative Analysis (Subject to Data Availability)

    • 13.1 Market Drivers
    • 13.2 Market Restraints
    • 13.3 Market Trends
    • 13.4 Market Opportunity
    • 13.5 Technological Road Map (Subject to Data Availability)
    • 13.6 Product Life Cycle (Subject to Data Availability)
    • 13.7 Customer and Buyer Behavior Analysis
      • 13.7.1 Digital Engagement, Customer Experience & Relationship Analysis
      • 13.7.2 Customer Buying Behavior & Purchase Decision Analysis
      • 13.7.3 Vendor Selection, Supplier Preferences & Future Demand Trends
      • 13.7.4 Pricing, Affordability & Value Perception Analysis
      • 13.7.5 Customer Segmentation & Demand Pattern Analysis
    • 13.8 Industrial Chain Analysis (Subject to Data Availability)
      • 13.8.1 Industry Chain Analysis
      • 13.8.2 Manufacturing Cost Analysis
      • 13.8.3 Supply Side Analysis
        • 13.8.3.1 Raw Material Analysis
        • 13.8.3.2 Raw Material Procurement Analysis
        • 13.8.3.3 Raw Material Price Trend Analysis
    • 13.9 PESTEL Analysis
      • 13.9.1 Environmental Factors
      • 13.9.2 Legal Factors
      • 13.9.3 Technological Factors
      • 13.9.4 Economic Factors
      • 13.9.5 Political Factors
      • 13.9.6 Social Factors
    • 13.10 Porter’s Five Forces Analysis
      • 13.10.1 Degree of Competition
      • 13.10.2 Threat of Substitutes
      • 13.10.3 Threat of New Entrants
      • 13.10.4 Bargaining Power of Buyers
      • 13.10.5 Bargaining Power of Suppliers
    • 13.11 Patent Analysis (Subject to Data Availability)
    • 13.12 ESG Analysis
    • 13.13 Geopolitical Outlook
      • 13.13.1 Global Power Realignment & Strategic Alliances
      • 13.13.2 Geopolitical Risk Landscape & Conflict Hotspots
      • 13.13.3 International Trade Relations & Market Access Environment
      • 13.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
      • 13.13.5 Supply Chain Resilience, Localization & Resource Nationalism
      • 13.13.6 Technology Sovereignty & Digital Geopolitics
      • 13.13.7 Strategic Implications for Investment, Growth & Market Entry
    • 13.14 AI & Market Transformation
      • 13.14.1 Competitive Landscape Disruption & Strategic Shifts
      • 13.14.2 AI-Driven Transformation of Industry Value Chain
      • 13.14.3 Evolution of Business Models & Revenue Streams
      • 13.14.4 AI-Driven Product, Service & Innovation Transformation
      • 13.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • Chapter 14. Research Findings

    • 14.1 Key Takeaways
    • 14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

  • Chapter 15. Research Methodology and Sources

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

Athenaeum AI Dashboard

Research Framework · 70:30 Primary:Secondary

Our Proprietary Methodology

Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the North America Human Insulin Market Analysis Market analysis.

01

Primary Intelligence Gathering

Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

02

Secondary Data Triangulation

Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

03

Expert Validation Protocol

Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

04

Athenaeum AI Processing

Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

05

Editorial & QA Review

Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

Data Assurance Metrics
Data Points Validated 10,400+
Expert Interviews 54
Countries Covered 39+
Company Profiles 11+
Forecast Accuracy (Historical) 94.2%
Analytical Coverage
Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

Sources from the Pharma and Healthcare Industry

How We Serve You

The Three Pillars of End-to-End Market Research Services

We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the North America Human Insulin Market Analysis market.

Service 01

Market Survey

B2B B2C

Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the north america human insulin market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

What's Included
  • Buyer intent & sentiment analysis
  • Purchase cycle mapping
  • Price sensitivity research
  • Channel preference profiling
  • Competitive perception study
Most Requested
Service 02

Customized Market Data & Reports

Custom Ready Report

Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

What's Included
  • Ready syndicate report
  • Custom data scope & segmentation
  • Excel quantitative models
  • Board-ready PPT with key findings
  • Secure cloud portal access
Service 03

Strategic Consultation

With Survey With Report

Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

What's Included
  • Dedicated analyst assigned to you
  • Live walkthrough of findings
  • Strategic Q&A sessions
  • Go-to-market recommendations
  • NDA-protected engagement

Customize This Report

Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.